Overview
Pharmaceutical ingredient producer's 2025 net sales fell 7% yr/yr
Outlook
EuroAPI expects 2026 net sales to decrease around 10% due to portfolio rationalization
Company aims to maintain FY 2026 Core EBITDA margin in line with FY 2025
Result Drivers
COST CONTROL - Effective cost control measures led to €10M decrease in OPEX, improving Core EBITDA margin
ASIAN COMPETITION - Intensified market pressure from Asian competitors affected sales of highly potent molecules
Company press release: ID:nGNE6yH5BR
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
EUR 848.2 mln
FY Net Income
-EUR 211.2 mln
FY Gross Profit Margin
17.1%
FY EBITDA
EUR 9.9 mln
FY Gross Profit
EUR 144.8 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Euroapi SA is €2.61, about 26.2% above its March 2 closing price of €2.07
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
